Literature DB >> 2680211

Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid.

P Netter1, B Bannwarth, M J Royer-Morrot.   

Abstract

Synovial fluid concentration is considered to be an important determinant of clinical response to non-steroidal anti-inflammatory drugs (NSAIDs). Trans-synovial transport of these drugs is a process of limited diffusion, governed partly by the pharmacological characteristics of NSAIDs and partly by the properties of the joint and joint space themselves. The studies which report simultaneous pharmacokinetics of NSAIDs in both plasma and synovial fluid compartments are of 2 types: (1) some compare the concurrent concentrations of drugs in plasma and joint fluid after a single administration. These provide pharmacokinetic information: (2) others, which conform more closely to the therapeutic conditions, look at synovial fluid and plasma concentrations after repeated administration of the drug. Recent findings on the pharmacokinetics of NSAIDs in synovial fluid are reviewed. These studies reveal 2 types of NSAIDs, according to their pharmacokinetic behaviour. First, there are NSAIDs with a short or intermediate plasma elimination half-life. These drugs equilibrate rapidly relative to their elimination; their peak synovial fluid concentrations occur later and are lower than those in plasma. Several hours after administration there is crossover of the concentration curves, and beyond this point, concentrations in synovial fluid may exceed those in plasma. During prolonged treatment, the synovial fluid concentrations of these NSAIDs fluctuate to a much lesser extent than plasma concentrations. Secondly, there are NSAIDs with a long plasma elimination half-life; their peak concentration in synovial fluid is also lower and later than that in plasma. At steady-state their concentrations (total and free) in synovial fluid are about half those in plasma. Numerous variables must be taken into account in attempts to correlate synovial fluid NSAIDs concentrations with clinical response, including protein binding and determination of both active metabolites and (eventually) the enantiomers.

Mesh:

Substances:

Year:  1989        PMID: 2680211     DOI: 10.2165/00003088-198917030-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  68 in total

1.  Stereoselective disposition of ibuprofen enantiomers in synovial fluid.

Authors:  R O Day; K M Williams; G G Graham; E J Lee; R D Knihinicki; G D Champion
Journal:  Clin Pharmacol Ther       Date:  1988-05       Impact factor: 6.875

2.  Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100 mg slow-release formulation.

Authors:  P D Fowler; P T Dawes; V A John; P A Shotton
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio.

Authors:  P H Hinderling; D Hartmann; C Crevoisier; U Moser; P Heizmann
Journal:  Ther Drug Monit       Date:  1988       Impact factor: 3.681

4.  The determination of naproxen by spectrofluorometry and its binding to serum proteins.

Authors:  A Mortensen; E B Jensen; P B Petersen; S Husted; F Andreasen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1979-04

5.  Problems with demonstrating NSAID concentration-response relationships.

Authors:  D M Grennan; L Aarons; R Salisbury
Journal:  Agents Actions Suppl       Date:  1985

6.  Gentisate, a salicylate metabolite with antioxidant properties.

Authors:  L G Cleland; M W Whitehouse; W H Betts
Journal:  Drugs Exp Clin Res       Date:  1985

7.  Total and free ketoprofen in serum and synovial fluid after intramuscular injection.

Authors:  P Netter; B Bannwarth; F Lapicque; J M Harrewyn; A Frydman; J N Tamisier; A Gaucher; R J Royer
Journal:  Clin Pharmacol Ther       Date:  1987-11       Impact factor: 6.875

8.  Some observations and speculations on the factors influencing the concentration of phenylbutazone in synovial fluid.

Authors:  M Farr; C F Hawkins; M J Kendall; J V Willis
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-12

9.  Osmosin: its effect on plasma and synovial fluid kinetics of indomethacin.

Authors:  P D Fowler; P T Dawes
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Dissociation of acetylsalicylic acid in blood and joint fluid.

Authors:  A Soren
Journal:  Scand J Rheumatol       Date:  1977       Impact factor: 3.641

View more
  21 in total

Review 1.  Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach.

Authors:  N M Davies; N M Skjodt
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

2.  Pharmacokinetics of diflunisal in patients.

Authors:  B Nuernberg; G Koehler; K Brune
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

Review 3.  Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs.

Authors:  A M Evans
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells.

Authors:  F Lapicque; P Vergne; J Y Jouzeau; D Loeuille; P Gillet; E Vignon; P Thomas; P Velicitat; D Türck; C Guillaume; A Gaucher; P Bertin; P Netter
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 5.  Synovial perfusion and synovial fluid solutes.

Authors:  P A Simkin
Journal:  Ann Rheum Dis       Date:  1995-05       Impact factor: 19.103

Review 6.  Articular pharmacokinetics of protein-bound antirheumatic agents.

Authors:  P A Simkin; M P Wu; D M Foster
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

7.  Modeling Sex Differences in Pharmacokinetics, Pharmacodynamics, and Disease Progression Effects of Naproxen in Rats with Collagen-Induced Arthritis.

Authors:  Xiaonan Li; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2017-02-28       Impact factor: 3.922

Review 8.  Pharmacokinetic optimisation of the treatment of osteoarthritis.

Authors:  K J Skeith; D R Brocks
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

9.  Pharmacokinetics of lumiracoxib in plasma and synovial fluid.

Authors:  Graham Scott; Christiane Rordorf; Christine Reynolds; Jyoti Kalbag; Michael Looby; Slavica Milosavljev; Margaret Weaver; John P Huff; Dennis A Ruff
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of ketorolac tromethamine.

Authors:  D R Brocks; F Jamali
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.